Literature DB >> 23829779

Characterization of cytotoxic T lymphocyte function after foot-and-mouth disease virus infection and vaccination.

Jared R Patch1, Mary Kenney, Juan M Pacheco, Marvin J Grubman, William T Golde.   

Abstract

The induction of neutralizing antibodies specific for foot-and-mouth disease virus (FMDV) has been the central goal of vaccination efforts against this economically important disease of cloven-hoofed animals. Although these efforts have yielded much success, challenges remain, including little cross-serotype protection and inadequate duration of immunity. Commonly, viral infections are characterized by induction of cytotoxic T lymphocytes (CTL), yet the function of CTL in FMDV immunity is poorly defined. We developed an assay for detection of CTL specific for FMDV and reported that a modified adenovirus-vectored FMDV vaccine could induce CTL activity. This allowed us to determine whether FMDV-specific CTL responses are induced during infection and to test further whether vaccine-induced CTL could protect against challenge with FMDV. We now show the induction of antigen-specific CTL responses after infection of swine with FMDV strain A24 Cruizero. In addition, we developed a vaccination strategy that induces FMDV-specific CTL in the absence of significant neutralizing antibody. Animals vaccinated using this protocol showed delayed clinical disease and significantly suppressed viremia compared to control animals, suggesting a role for CTLs in the control of virus shedding. These results provide new insights showing induction of CTL responses to FMDV following infection or vaccination, and create the potential for improving vaccine performance by targeting cellular immunity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23829779      PMCID: PMC3739958          DOI: 10.1089/vim.2013.0011

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  56 in total

Review 1.  Control of foot and mouth disease: lessons from the experience of the outbreak in Great Britain in 2001.

Authors:  J M Scudamore; D M Harris
Journal:  Rev Sci Tech       Date:  2002-12       Impact factor: 1.181

Review 2.  Control and eradication of foot-and-mouth disease.

Authors:  Paul Sutmoller; Simon S Barteling; Raul Casas Olascoaga; Keith J Sumption
Journal:  Virus Res       Date:  2003-01       Impact factor: 3.303

Review 3.  FMD vaccines.

Authors:  T R Doel
Journal:  Virus Res       Date:  2003-01       Impact factor: 3.303

4.  Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate.

Authors:  G A Mayr; J Chinsangaram; M J Grubman
Journal:  Virology       Date:  1999-10-25       Impact factor: 3.616

5.  Induction of lymphopenia and inhibition of T cell function during acute infection of swine with foot and mouth disease virus (FMDV).

Authors:  Elida M Bautista; Geoffrey S Ferman; William T Golde
Journal:  Vet Immunol Immunopathol       Date:  2003-03-20       Impact factor: 2.046

6.  Induction of a cross-reactive CD8(+) T cell response following foot-and-mouth disease virus vaccination.

Authors:  Efrain Guzman; Geraldine Taylor; Bryan Charleston; Shirley A Ellis
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

7.  Evidence for positive selection in foot-and-mouth disease virus capsid genes from field isolates.

Authors:  D T Haydon; A D Bastos; N J Knowles; A R Samuel
Journal:  Genetics       Date:  2001-01       Impact factor: 4.562

8.  Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs.

Authors:  G A Mayr; V O'Donnell; J Chinsangaram; P W Mason; M J Grubman
Journal:  Vaccine       Date:  2001-02-28       Impact factor: 3.641

9.  Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24.

Authors:  M P Moraes; G A Mayr; P W Mason; M J Grubman
Journal:  Vaccine       Date:  2002-02-22       Impact factor: 3.641

10.  Use of a portable real-time reverse transcriptase-polymerase chain reaction assay for rapid detection of foot-and-mouth disease virus.

Authors:  Johnny D Callahan; Fred Brown; Fernando A Osorio; Jung H Sur; Ed Kramer; Gary W Long; Juan Lubroth; Stefanie J Ellis; Katina S Shoulars; Kristin L Gaffney; Daniel L Rock; William M Nelson
Journal:  J Am Vet Med Assoc       Date:  2002-06-01       Impact factor: 1.936

View more
  4 in total

1.  A modern approach for epitope prediction: identification of foot-and-mouth disease virus peptides binding bovine leukocyte antigen (BoLA) class I molecules.

Authors:  Mital Pandya; Michael Rasmussen; Andreas Hansen; Morten Nielsen; Soren Buus; William Golde; John Barlow
Journal:  Immunogenetics       Date:  2015-11       Impact factor: 2.846

2.  Systemic immune response and virus persistence after foot-and-mouth disease virus infection of naïve cattle and cattle vaccinated with a homologous adenovirus-vectored vaccine.

Authors:  Michael Eschbaumer; Carolina Stenfeldt; Steven I Rekant; Juan M Pacheco; Ethan J Hartwig; George R Smoliga; Mary A Kenney; William T Golde; Luis L Rodriguez; Jonathan Arzt
Journal:  BMC Vet Res       Date:  2016-09-15       Impact factor: 2.741

Review 3.  Foot-and-Mouth Disease Virus: Immunobiology, Advances in Vaccines and Vaccination Strategies Addressing Vaccine Failures-An Indian Perspective.

Authors:  Raj Kumar Singh; Gaurav Kumar Sharma; Sonalika Mahajan; Kuldeep Dhama; Suresh H Basagoudanavar; Madhusudan Hosamani; B P Sreenivasa; Wanpen Chaicumpa; Vivek Kumar Gupta; Aniket Sanyal
Journal:  Vaccines (Basel)       Date:  2019-08-16

4.  Pigs that recover from porcine reproduction and respiratory syndrome virus infection develop cytotoxic CD4+CD8+ and CD4+CD8- T-cells that kill virus infected cells.

Authors:  Chungwon J Chung; Sang-Ho Cha; Amanda L Grimm; Dharani Ajithdoss; Joanna Rzepka; Grace Chung; Jieun Yu; William C Davis; Chak-Sum Ho
Journal:  PLoS One       Date:  2018-09-06       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.